Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$60.14M+146.38%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Siddhartha C. Kadia
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 717
- Beta
- 0.96
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.20
Financials
Revenue
$60.14M+146.4%Net Income
$2.83M+20.0%EBITDA
$12.36M+97.7%Free Cash Flow
$14.18MEPS (diluted)
$0.49-21.0%Shares Outstanding (diluted)
5.76M+50.3%Operating Expenses
$22.11MCash & Debt
$30.70MReturn of Capital
$884.0KRevenue by Segment (annual)
$249.13MDividend per Share
$0.16Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $249.13M | $6.71M | $1.22 |
| 2025 | $240.98M | $-1.97M | $-0.36 |
| 2024 | $216.19M | $-254.25M | $-47.20 |
| 2023 | $219.08M | $930.0K | $0.17 |
| 2022 | $184.34M | $1.87M | $0.36 |
| 2021 | $133.94M | $3.27M | $0.66 |
| 2020 | $117.69M | $1.78M | $0.32 |
| 2019 | $103.14M | $7.48M | $1.95 |
| 2018 | $96.18M | $-2.96M | $-0.79 |
| 2017 | $93.67M | $11.18M | $3.04 |
| 2016 | $84.66M | $11.17M | $3.10 |
| 2015 | $71.33M | $9.58M | $2.72 |
| 2014 | $52.72M | $9.00M | $2.61 |
| 2013 | $46.44M | $8.45M | $2.52 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MLAB's reported EPS growth of -5.4% a year over 13 years.
- EPS in 5 years
- $0.92
- Implied price
- $16.60
- Return from $142.23
- -34.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.25 — -94.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -15.4% | -46.3% | -43.9% | -41.8% | -40.0% | -38.4% |
| -10.4% | -43.2% | -40.6% | -38.4% | -36.4% | -34.7% |
| -5.4% | -40.0% | -37.3% | -34.9% | -32.9% | -31.1% |
| -0.4% | -36.8% | -33.9% | -31.5% | -29.3% | -27.4% |
| 4.6% | -33.6% | -30.6% | -28.0% | -25.8% | -23.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (3)
- Newsgurufocus.com·33d ago·Neutral
Mesa Laboratories Inc (MLAB) Shares Surge 4.1% -- What GF Score of 75 Tells Investors On September 02, 2026, Mesa Laboratories Inc (MLAB) shares rose 4.1% to $130.65, reflecting a significant increase within a volatile 52-week range of $58.83 to
View source ↗ - Newsseekingalpha.com·56d ago·Positive
Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·56d ago·Negative
Mesa Laboratories Q1 Earnings Call Highlights Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $2.29 per share
Typical surprise +1.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 10$2.68 vs $2.63beat
- Wed, May 27$2.76 vs $2.09beat
- Tue, Feb 3$3.07 vs $1.40beat
- Thu, Nov 6$1.76 vs $2.30miss
- Tue, Aug 5$2.32 vs $2.46miss
- Wed, May 28$2.23 vs $2.75miss
Estimates and results for MLAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MLAB officers and directors.
- Bought
- $1.4m
- Sold
- $1.6m
5 trades
7 trades
- Sullivan John Jamessold
- Kadia Siddharthabought
- Tripeny R Tonybought
- Crennen Lyndsey Elizabethsold
- Archbold Brian Davidsold
- Sakys Johnsold
- Archbold Brian Davidsold
- Crennen Lyndsey Elizabethsold
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MLAB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.